On this page

Bethanechol Chloride

Prescription ANDA TE AA Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Bethanechol Chloride
Generic name
Bethanechol Chloride
Dosage form
Tablet
Route
Oral
Marketing category
ANDA · ANDA
Labeler
Amneal Pharmaceuticals of New York LLC
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
4
NDC product codes
22
Packages
41
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Bethanechol Chloride 10 mg/1 857321 —
Bethanechol Chloride 25 mg/1 857321 —
Bethanechol Chloride 5 mg/1 857321 —
Bethanechol Chloride 50 mg/1 857321 —

Forms, strengths and routes

Source: NDC Directory
Dosage form
Tablet
Route of administration
Oral
Presentations
63

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Cholinergic Muscarinic Agonist [EPC] EPC 2 members — no class page
Cholinergic Muscarinic Agonists [MoA] MoA 8 members — no class page

Regulatory status

Source: Drugs@FDANDC Directory
Application number
040855
Application type
ANDA · Abbreviated New Drug Application
Approval date
November 21, 2007
Sponsor
AMNEAL PHARM
Products on application
4
Submissions recorded
1
Products approved under application 040855.
Product Trade name Form Strength Ingredient Status TE Flags
040855-001 BETHANECHOL CHLORIDE TABLET BETHANECHOL CHLORIDE Prescription AA RS
040855-002 BETHANECHOL CHLORIDE TABLET BETHANECHOL CHLORIDE Prescription AA RS
040855-003 BETHANECHOL CHLORIDE TABLET BETHANECHOL CHLORIDE Prescription AA RS
040855-004 BETHANECHOL CHLORIDE TABLET BETHANECHOL CHLORIDE Prescription AA RS

Therapeutic equivalence

Source: Orange Book
TE code
AA
Reference Listed Drug
No
Reference Standard
Yes

What this rating means: Therapeutically equivalent — no known or suspected bioequivalence problems (conventional dosage forms)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 040855.
Type No. Action Status Date Review
Original application 1 Approved November 21, 2007 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260129). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260129 HUMAN PRESCRIPTION DRUG · 20251216 HUMAN PRESCRIPTION DRUG · 20241202 HUMAN PRESCRIPTION DRUG · 20241023

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Bethanechol Chloride Tablets, USP are indicated for the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Dosage must be individualized, depending on the type and severity of the condition to be treated. Preferably give the drug when the stomach is empty. If taken soon after eating, nausea and vomiting may occur. The usual adult oral dose ranges from 10 mg to 50 mg three or four times a day. The minimum effective dose is determined by giving 5 mg to 10 mg initially, and repeating the same amount at hourly intervals until satisfactory response occurs, or until a maximum of 50 mg has been given. The effects of the drug sometimes appear within 30 minutes, and are usually maximal within 60 to 90 minutes. The drug effects persist for about one hour. If necessary, the effects of the drug can be abolished promptly by atropine (see OVERDOSAGE ).

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Hypersensitivity to bethanechol chloride tablets, hyperthyroidism, peptic ulcer, latent or active bronchial asthma, pronounced bradycardia or hypotension, vasomotor instability, coronary artery disease, epilepsy and parkinsonism. Bethanechol chloride should not be employed when the strength or integrity of the gastrointestinal or bladder wall is in question, or in the presence of mechanical obstruction; when increased muscular activity of the gastrointestinal tract or urinary bladder might prove harmful, as following recent urinary bladder surgery, gastrointestinal resection and anastomosis, or when there is possible gastrointestinal obstruction; in bladder neck obstruction, spastic gastrointestinal disturbances, acute inflammatory lesions of the gastrointestinal tract, or peritonitis; or in marked vagotonia.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Adverse reactions are rare following oral administration of bethanechol chloride, but are more common following subcutaneous injection. Adverse reactions are more likely to occur when dosage is increased. The following adverse reactions have been observed: Body as a Whole: malaise Digestive: abdominal cramps or discomfort, colicky pain, nausea and belching, diarrhea, borborygmi, salivation Renal: urinary urgency Nervous System: headache Cardiovascular: a fall in blood pressure with reflex tachycardia, vasomotor response Skin: flushing producing a feeling of warmth, sensation of heat about the face, sweating Respiratory: bronchial constriction, asthmatic attacks Special Senses : lacrimation, miosis Causal Relationship Unknown: The following adverse reactions have been reported, and a causal relationship to therapy with bethanechol chloride has not been established: Body as a Whole: malaise Nervous System: seizures To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Drug Interactions

openFDA Drug Labeling

Drug Interactions Special care is required if this drug is given to patients receiving ganglion blocking compounds because a critical fall in blood pressure may occur. Usually, severe abdominal symptoms appear before there is such a fall in the blood pressure.

Description

openFDA Drug Labeling

DESCRIPTION Bethanechol chloride, a cholinergic agent, is a synthetic ester which is structurally and pharmacologically related to acetylcholine. It is designated chemically as 2-[(aminocarbonyl) oxy]- N,N,N -trimethyl-1-propanaminium chloride. Its molecular formula is C 7 H 17 CIN 2 O 2 and its structural formula is: Bethanechol chloride, USP is a white, hygroscopic crystalline powder having a slight amine-like odor, freely soluble in water, and has a molecular weight of 196.68. Each tablet for oral administration contains 5 mg, 10 mg, 25 mg or 50 mg bethanechol chloride, USP. Bethanechol chloride Tablets, USP also contain the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose and sodium starch glycolate, Type A. The 25 mg and 50 mg tablets also contain D&C Yellow No.10 Aluminum Lake and FD&C Yellow No. 6 Aluminum Lake. Structural Formula

OVERDOSAGE Early signs of overdosage are abdominal discomfort, salivation, flushing of the skin (“hot feeling”), sweating, nausea, and vomiting. Atropine Sulfate is a specific antidote. The recommended dose for adults is 0.6 mg. Repeat doses can be given every two hours, according to clinical response. The recommended dosage in infants and children up to 12 years of age is 0.01 mg/kg (to a maximum single dose of 0.4 mg) repeated every two hours as needed until the desired effect is obtained or adverse effects of atropine preclude further usage. Subcutaneous injection of atropine is preferred except in emergencies when the intravenous route may be employed. The oral LD 50 of bethanechol chloride is 1,510 mg/kg in the mouse.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Bethanechol Chloride Tablets, USP, 5 mg are supplied as white, round, flat-faced, bevelled tablets debossed with ‘AN’ above bisect and ‘571’ below bisect on one side and plain on the other side. They are available as follows: Bottle of 100: NDC 65162-571-10 Bottle of 500: NDC 65162-571-50 Bottle of 1000: NDC 65162-571-11 Bethanechol Chloride Tablets, USP, 10 mg are supplied as white, round, flat-faced, bevelled tablets debossed with ‘AN’ above bisect and ‘572’ below bisect on one side and plain on the other side. They are available as follows: Bottle of 100: NDC 65162-572-10 Bottle of 500: NDC 65162-572-50 Bottle of 1000: NDC 65162-572-11 Bethanechol Chloride Tablets, USP, 25 mg are supplied as yellow, round, flat-faced, bevelled tablets debossed with ‘AN’ above bisect and ‘573’ below bisect on one side and plain on the other side. They are available as follows: Bottle of 100: NDC 65162-573-10 Bottle of 500: NDC 65162-573-50 Bottle of 1000: NDC 65162-573-11 Bethanechol Chloride Tablets, USP, 50 mg are supplied as yellow, round, flat-faced, bevelled tablets debossed with ‘AN’ above bisect and ‘574’ below bisect on one side and plain on the other side. They are available as follows: Bottle of 100: NDC 65162-574-10 Bottle of 500: NDC 65162-574-50 Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. This container is not intended for household use. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 Rev. 05-2018-03

Adverse event reports

Source: openFDA FAERS
546
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: BETHANECHOL CHLORIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
60687-689-01 60687-689 American Health Packaging 100 BLISTER PACK in 1 CARTON (60687-689-01) / 1 TABLET in 1 BLISTER PACK (60687-689-11) August 17, 2022
60687-700-01 60687-700 American Health Packaging 100 BLISTER PACK in 1 CARTON (60687-700-01) / 1 TABLET in 1 BLISTER PACK (60687-700-11) December 15, 2022
65162-571-10 65162-571 Amneal Pharmaceuticals LLC 100 TABLET in 1 BOTTLE (65162-571-10) November 21, 2007
65162-571-11 65162-571 Amneal Pharmaceuticals LLC 1000 TABLET in 1 BOTTLE (65162-571-11) November 21, 2007
65162-571-50 65162-571 Amneal Pharmaceuticals LLC 500 TABLET in 1 BOTTLE (65162-571-50) November 21, 2007
65162-572-10 65162-572 Amneal Pharmaceuticals LLC 100 TABLET in 1 BOTTLE (65162-572-10) November 21, 2007
65162-572-11 65162-572 Amneal Pharmaceuticals LLC 1000 TABLET in 1 BOTTLE (65162-572-11) November 21, 2007
65162-572-50 65162-572 Amneal Pharmaceuticals LLC 500 TABLET in 1 BOTTLE (65162-572-50) November 21, 2007
65162-573-10 65162-573 Amneal Pharmaceuticals LLC 100 TABLET in 1 BOTTLE (65162-573-10) November 21, 2007
65162-573-11 65162-573 Amneal Pharmaceuticals LLC 1000 TABLET in 1 BOTTLE (65162-573-11) November 21, 2007
65162-573-50 65162-573 Amneal Pharmaceuticals LLC 500 TABLET in 1 BOTTLE (65162-573-50) November 21, 2007
65162-574-10 65162-574 Amneal Pharmaceuticals LLC 100 TABLET in 1 BOTTLE (65162-574-10) November 21, 2007
65162-574-50 65162-574 Amneal Pharmaceuticals LLC 500 TABLET in 1 BOTTLE (65162-574-50) November 21, 2007
53746-571-01 53746-571 Amneal Pharmaceuticals of New York LLC 100 TABLET in 1 BOTTLE (53746-571-01) April 15, 2022
53746-572-01 53746-572 Amneal Pharmaceuticals of New York LLC 100 TABLET in 1 BOTTLE (53746-572-01) April 15, 2022
53746-573-01 53746-573 Amneal Pharmaceuticals of New York LLC 100 TABLET in 1 BOTTLE (53746-573-01) April 15, 2022
53746-574-01 53746-574 Amneal Pharmaceuticals of New York LLC 100 TABLET in 1 BOTTLE (53746-574-01) April 15, 2022
62135-755-90 62135-755 Chartwell RX, LLC 90 TABLET in 1 BOTTLE (62135-755-90) January 17, 2024
62135-756-12 62135-756 Chartwell RX, LLC 120 TABLET in 1 BOTTLE (62135-756-12) January 17, 2024
62135-757-12 62135-757 Chartwell RX, LLC 120 TABLET in 1 BOTTLE (62135-757-12) January 17, 2024
62135-758-12 62135-758 Chartwell RX, LLC 120 TABLET in 1 BOTTLE (62135-758-12) January 17, 2024
23155-934-01 23155-934 Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. 100 TABLET in 1 BOTTLE (23155-934-01) June 30, 2025
23155-935-01 23155-935 Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. 100 TABLET in 1 BOTTLE (23155-935-01) June 30, 2025
23155-936-01 23155-936 Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. 100 TABLET in 1 BOTTLE (23155-936-01) June 30, 2025
23155-937-01 23155-937 Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. 100 TABLET in 1 BOTTLE (23155-937-01) June 30, 2025
0832-0510-00 0832-0510 Upsher-Smith Laboratories, LLC 100 TABLET in 1 BOTTLE (0832-0510-00) January 24, 2010
0832-0510-01 0832-0510 Upsher-Smith Laboratories, LLC 100 BLISTER PACK in 1 CARTON (0832-0510-01) / 1 TABLET in 1 BLISTER PACK (0832-0510-89) January 24, 2010
0832-0510-10 0832-0510 Upsher-Smith Laboratories, LLC 1000 TABLET in 1 BOTTLE (0832-0510-10) January 24, 2010
0832-0511-00 0832-0511 Upsher-Smith Laboratories, LLC 100 TABLET in 1 BOTTLE (0832-0511-00) January 24, 2010
0832-0511-01 0832-0511 Upsher-Smith Laboratories, LLC 100 BLISTER PACK in 1 CARTON (0832-0511-01) / 1 TABLET in 1 BLISTER PACK (0832-0511-89) January 24, 2010
0832-0511-10 0832-0511 Upsher-Smith Laboratories, LLC 1000 TABLET in 1 BOTTLE (0832-0511-10) January 24, 2010
0832-0511-25 0832-0511 Upsher-Smith Laboratories, LLC 250 TABLET in 1 BOTTLE (0832-0511-25) January 24, 2010
0832-0512-00 0832-0512 Upsher-Smith Laboratories, LLC 100 TABLET in 1 BOTTLE (0832-0512-00) January 24, 2010
0832-0512-01 0832-0512 Upsher-Smith Laboratories, LLC 100 BLISTER PACK in 1 CARTON (0832-0512-01) / 1 TABLET in 1 BLISTER PACK (0832-0512-89) January 24, 2010
0832-0512-10 0832-0512 Upsher-Smith Laboratories, LLC 1000 TABLET in 1 BOTTLE (0832-0512-10) January 24, 2010
0832-0512-25 0832-0512 Upsher-Smith Laboratories, LLC 250 TABLET in 1 BOTTLE (0832-0512-25) January 24, 2010
0832-0512-50 0832-0512 Upsher-Smith Laboratories, LLC 500 TABLET in 1 BOTTLE (0832-0512-50) January 24, 2010
0832-0513-00 0832-0513 Upsher-Smith Laboratories, LLC 100 TABLET in 1 BOTTLE (0832-0513-00) January 24, 2010
0832-0513-01 0832-0513 Upsher-Smith Laboratories, LLC 100 BLISTER PACK in 1 CARTON (0832-0513-01) / 1 TABLET in 1 BLISTER PACK (0832-0513-89) January 24, 2010
0832-0513-10 0832-0513 Upsher-Smith Laboratories, LLC 1000 TABLET in 1 BOTTLE (0832-0513-10) January 24, 2010
0832-0513-50 0832-0513 Upsher-Smith Laboratories, LLC 500 TABLET in 1 BOTTLE (0832-0513-50) January 24, 2010
60687-689 60687-689 American Health Packaging — August 17, 2022
60687-700 60687-700 American Health Packaging — December 15, 2022
65162-571 65162-571 Amneal Pharmaceuticals LLC — November 21, 2007
65162-572 65162-572 Amneal Pharmaceuticals LLC — November 21, 2007
65162-573 65162-573 Amneal Pharmaceuticals LLC — November 21, 2007
65162-574 65162-574 Amneal Pharmaceuticals LLC — November 21, 2007
53746-571 53746-571 Amneal Pharmaceuticals of New York LLC — April 15, 2022
53746-572 53746-572 Amneal Pharmaceuticals of New York LLC — April 15, 2022
53746-573 53746-573 Amneal Pharmaceuticals of New York LLC — April 15, 2022
53746-574 53746-574 Amneal Pharmaceuticals of New York LLC — April 15, 2022
62135-755 62135-755 Chartwell RX, LLC — October 26, 2007
62135-756 62135-756 Chartwell RX, LLC — October 26, 2007
62135-757 62135-757 Chartwell RX, LLC — October 26, 2007
62135-758 62135-758 Chartwell RX, LLC — October 26, 2007
23155-934 23155-934 Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. — June 30, 2025
23155-935 23155-935 Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. — June 30, 2025
23155-936 23155-936 Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. — June 30, 2025
23155-937 23155-937 Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. — June 30, 2025
0832-0510 0832-0510 Upsher-Smith Laboratories, LLC — January 24, 2010
0832-0511 0832-0511 Upsher-Smith Laboratories, LLC — January 24, 2010
0832-0512 0832-0512 Upsher-Smith Laboratories, LLC — January 24, 2010
0832-0513 0832-0513 Upsher-Smith Laboratories, LLC — January 24, 2010

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.